Consequently, the benefits of prostate cancer screening using PSA and DRE is still controversial within the medical and scientific community due to the fact that each test is more likely to detect cancers of unknown clinical significance and fail to distinguish life threatening tumors which might remain in a latent stage, making it difficult to understand the natural progression of the disease. This evidence concerns the gene KLK3 and prostate carcinoma.